[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633291":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":28,"locations":37,"responsibleParty":52,"collaborators":11,"id":56,"slug":11,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":11,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":11,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":11,"overallStatus":39,"whyStopped":11,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Zhejiang Cancer Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Sporoderm-removed Ganoderma lucidum spore powder (RGLS)","EXPERIMENTAL",null,[13],"Dietary Supplement: Sporoderm-removed Ganoderma lucidum spore powder (RGLS)",{"label":15,"type":16,"description":11,"interventionNames":17},"placebo group","PLACEBO_COMPARATOR",[18],"Other: Placebo",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":11},"DIETARY_SUPPLEMENT","From the first day after enrollment, subjects take RGLS orally at 4g\u002Fday for 3 months.",[9],{"type":6,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"Placebo","From the first day after enrollment, subjects take placebo orally at 4g\u002Fday for 3 months.",[15],[29,34],{"name":30,"role":31,"phone":32,"phoneExt":11,"email":33},"Zhiqiang Ling","CONTACT","+86-571-88122423","lingzq@zjcc.org.cn",{"name":35,"role":31,"phone":11,"phoneExt":11,"email":36},"Jinbiao Shang","shangjb@zjcc.org.cn",[38],{"facility":5,"status":39,"city":40,"state":41,"zip":42,"country":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"RECRUITING","Hangzhou","Zhejiang","310022","China",{"type":45,"coordinates":46},"Point",[47,48],120.16142,30.29365,{"lat":48,"lon":47},[51],{"name":30,"role":31,"phone":32,"phoneExt":11,"email":33},{"type":53,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"SPONSOR_INVESTIGATOR","Ling Zhiqiang","Prof., M.D., PhD,","100633291",false,"NCT07524777","Ganoderma Spores Modulate the Gut-Brain Axis","Targeting the Gut-Brain Axis With Ganoderma Lucidum Spores Ameliorates Depression in Thyroid Cancer Patients: a Randomized, Double-blind, Placebo-controlled Trial","Inclusion Criteria:\n\n* Outpatients at Zhejiang Cancer Hospital with histologically confirmed papillary thyroid carcinoma (post-surgery) and depressive symptoms (HAMD-24 score ≥ 8, confirmed by a clinical psychologist).\n* Han Chinese ethnicity.\n* No history of depression or other psychiatric disorders.\n* Age 18-80 years.\n* Female.\n\nExclusion Criteria:\n\n* Suffering from other gastrointestinal system diseases.\n* History of gastrointestinal surgery prior to intervention.\n* Including those with other concurrent malignancies requiring chemotherapy, radiotherapy, biological therapy, or traditional Chinese medicine treatment.\n* Received antibiotic treatment or microecological modulators within 3 months prior to intervention.\n* Acute intestinal obstruction.\n* Patients who are currently taking antidepressant medication, or those whom the investigators judge require immediate initiation of antidepressant medication treatment.\n* Organic brain diseases, brain trauma.\n* History of psychiatric disorders, use of psychoactive substances (e.g., drugs).\n* Severe liver or kidney dysfunction.\n* Pregnancy or lactation.","FEMALE","18 Years","80 Years",{"count":66,"type":67},300,"ESTIMATED","INTERVENTIONAL",[70],"NA","This study aims to investigate whether Sporoderm-removed Ganoderma lucidum spore powder (RGLS) ameliorates depression in thyroid cancer patients through gut-brain axis modulation, and to elucidate the underlying microbial and metabolic mechanisms. This 3-month randomized, double-blind, placebo-controlled trial will enroll 300 postoperative papillary thyroid carcinoma patients with depressive symptoms (HAMD-24 ≥ 8). Participants will be randomly assigned(2 : 1) to receive RGLS (4 g\u002Fday) or matched placebo.",[73,74],"Depression","Thyroid Cancer","2026-05-07",{"date":77,"type":78},"2026-05-12","ACTUAL",{"date":80,"type":78},"2026-04-11",{"date":82,"type":67},"2026-08-31",{"name":54,"class":6},1]